Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Title
Intervention Indication Therapeutic Area Year Actions
Sotagliflozin for type 2 diabetes mellitus Sotagliflozin (Zynquista; SAR439954; LX4211) Type 2 diabetes Endocrine Nutritional and Metabolic Disorders 2019 View  |  Download
Setmelanotide for rare genetic obesity due to leptin receptor deficiency Setmelanotide (RM-493) Obesity due to Leptin receptor deficiency Endocrine Nutritional and Metabolic Disorders 2019 View  |  Download
Selumetinib for neurofibromatosis type 1 Selumetinib (AZD6244; ARRY-142886) Neurofibromatosis Neurology 2019 View  |  Download
Selpercatinib for metastatic RET fusion-positive non-small cell lung cancer Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Selpercatinib for advanced thyroid cancer with RET alterations Selpercatinib (LOXO-292; LY3527723) Medullary thyroid cancer (MTC) , Thyroid cancer Head and Neck Cancer , Oncology 2019 View  |  Download
Secukinumab for moderate to severe plaque psoriasis in children aged 6 to less than 18 years old Secukinumab (Cosentyx; AIN457) Plaque psoriasis Dermatology 2019 View  |  Download
Secukinumab for enthesitis-related arthritis and juvenile psoriatic arthritis in children and adolescents from the age of 2 years Secukinumab (Cosentyx; AIN457) Enthesitis-related arthritis , Juvenile psoriatic arthritis Rheumatology 2019 View  |  Download
Savolitinib for MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma Savolitinib (AZD6094) Renal cell carcinoma (RCC) Renal Cancer 2019 View  |  Download
Ruxolitinib for chronic graft versus host disease (cGvHD) Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2019 View  |  Download
Ruxolitinib for acute graft versus host disease (aGvHD) Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications